Heart-lung transplantation: better use of resources.
OBJECTIVE
Our goal was to review the experience at Papworth Hospital, Cambridgeshire, England, with combined heart-lung transplantation.


METHODS
Since April 1984, 31 patients have undergone heart-lung transplantation. Donors and recipients are carefully matched with regards to serology, morphology, and cytomegalovirus compatibility. A pulmonary preservation fluid has been developed that allows distant organ procurement with a single pulmonary artery flush technique.


RESULTS
Acute cardiac rejection has not occurred in these patients. Twenty-three patients are alive between two months and over three years following transplantation. The actuarial survival rate at one year is 78 percent, and 70 percent at two years. Three patients died as a result of cytomegalovirus pneumonitis; in two patients, obliterative bronchiolitis developed, and both died, one after an opportunistic infection developed. Three patients died from other causes. The use of transbronchial biopsy of the lung has provided accurate, early, and safe diagnosis of pulmonary rejection.


CONCLUSIONS
Developments in organ preservation and patient management, as well as careful selection of recipients and donors, have led to the effective use of resources and thereby to these good results. In particular, the incidence of obliterative bronchiolitis has been low, which is attributed to the early treatment of pulmonary rejection following diagnosis by transbronchial biopsy.
Hutter
J A
JA
Department of Surgery, Papworth Hospital, Cambridgeshire, England.
Despins
P
P
Higenbottam
T
T
Stewart
S
S
Wallwork
J
J
D000293:Adolescent; D000328:Adult; D003586:Cytomegalovirus Infections / Q000175:diagnosis; D004541:Eisenmenger Complex / Q000628:therapy*; D004739:England; D005260:Female; D006084:Graft Rejection; D006331:Heart Diseases / Q000628:therapy*; D016027:Heart Transplantation; D016041:Heart-Lung Transplantation; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008171:Lung Diseases / Q000628:therapy*; D016040:Lung Transplantation; D008297:Male; D008875:Middle Aged; D009926:Organ Preservation; D011183:Postoperative Complications / Q000401:mortality*
D007166:Immunosuppressive Agents